Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02169934 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects
A Phase 1 study, sponsored by Trevena.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02169934: Completed Phase 1 study, sponsored by Trevena.
NCT02169934 is a Phase 1 study that has completed, run by Trevena. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02169934, a Phase 1 study, has completed, sponsored by Trevena.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the routes of excretion for TRV130 and it's metabolites, and to determine and characterize, structurally, the metabolites present in plasma, urine, and feces in healthy male subjects.
Interventions
- DRUG Radiolabeled TRV130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT02169934 record still lists
NCT02169934 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Radiolabeled TRV130 is the first listed.
NCT02169934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02169934 about?
NCT02169934 is a clinical study titled "A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects". The purpose of this study is to determine the routes of excretion for TRV130 and it's metabolites, and to determine and characterize, structurally, the metabolites present in plasma, urine, and feces in healthy male subjects.
What is the current status of trial NCT02169934?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02169934?
The interventions under investigation include: Radiolabeled TRV130 (DRUG).
Who is sponsoring clinical trial NCT02169934?
This trial is sponsored by Trevena, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02169934's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia